AKT1 and metabolic syndrome: Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [2,3].